. "Lenalidomide is a promising new drug in the treatment of patients with multiple myeloma. Performed clinical studies Phase I and II have shown efficacy in patients with relapsed multiple myeloma. Subsequently, large randomized trials demonstrated the benefit of combined therapy in relapsed/refractory multiple myeloma patients with a combination of lenalidomide plus dexamethasone compared with dexamethasone treatment alone. Patients treated with a combination of lenalidomide and dexamethasone had significantly higher therapeutic response and overall survival than patients treated with dexamethasone alone. Profound toxicity seems to be the myelosuppressive effect of lenalidomide. The work gives a summary of the information available on lenalidomide in the treatment of multiple myeloma."@en . "Pou\u017Eit\u00ED lenalidomidu v l\u00E9\u010Db\u011B mnoho\u010Detn\u00E9ho myelomu" . . "H\u00E1jek, Roman" . . "Pou\u017Eit\u00ED lenalidomidu v l\u00E9\u010Db\u011B mnoho\u010Detn\u00E9ho myelomu"@cs . "Pou\u017Eit\u00ED lenalidomidu v l\u00E9\u010Db\u011B mnoho\u010Detn\u00E9ho myelomu" . "Klinick\u00E1 onkologie" . "RIV/00216224:14110/10:00044413" . "[2100EECF8145]" . . . "6"^^ . . "Hol\u00E1nek, Michal" . "RIV/00216224:14110/10:00044413!RIV11-MSM-14110___" . "2" . . "multiple myeloma; lenalidomide"@en . "Lenalidomid je nov\u00FD perspektivn\u00ED l\u00E9k v l\u00E9\u010Db\u011B pacient\u016F s mnoho\u010Detn\u00FDm myelomem. Tento analog thalidomidu vznikl s \u00FAmyslem zlep\u0161en\u00ED protin\u00E1dorov\u00E9ho p\u016Fsoben\u00ED, imunomodula\u010Dn\u00EDch vlastnost\u00ED, ale t\u00E9\u017E sn\u00ED\u017Een\u00ED toxicity prepar\u00E1tu. Mechanizmem protin\u00E1dorov\u00E9ho p\u016Fsoben\u00ED prepar\u00E1tu se zd\u00E1 b\u00FDt p\u016Fsoben\u00ED na bun\u011B\u010Dn\u00E9 slo\u017Eky, mikroprost\u0159ed\u00ED tumoru a zejm\u00E9na regulace produkce cytokinin\u016F. Prob\u011Bhl\u00E9 klinick\u00E9 studie f\u00E1ze I a II prok\u00E1zaly \u00FA\u010Dinnost u pacient\u016F s relabovan\u00FDm mnoho\u010Detn\u00FDm myelomem. N\u00E1sledn\u011B velk\u00E9 randomizovan\u00E9 studie prok\u00E1zaly v\u00FDhodnost terapie u relaxovan\u00FDch/ refraktern\u00EDch pacient\u016F s mnoho\u010Detn\u00FDm myelomem kombinac\u00ED lenalidomidu s dexametazonem oproti l\u00E9\u010Db\u011B dexametazonem v monoterapii. Pacienti l\u00E9\u010Den\u00ED kombinac\u00ED lenalidomidu s dexametazonem m\u011Bli v\u00FDznamn\u011B vy\u0161\u0161\u00ED l\u00E9\u010Debnou odpov\u011B\u010F i celkov\u00E9 p\u0159e\u017Eit\u00ED ne\u017E pacienti l\u00E9\u010Den\u00ED samotn\u00FDm dexametazonem. Z\u00E1sadn\u00ED toxicitou se zd\u00E1 b\u00FDt myelosupresivn\u00ED vliv lenalidomidu. Pr\u00E1ce p\u0159in\u00E1\u0161\u00ED shrnut\u00ED dostupn\u00FDch informac\u00ED o lenalidomidu v l\u00E9\u010Db\u011B mnoho\u010Detn\u00E9ho myelomu." . "280538" . . "2"^^ . "The use of lenalidomide in the treatment of multiple myeloma"@en . "Pou\u017Eit\u00ED lenalidomidu v l\u00E9\u010Db\u011B mnoho\u010Detn\u00E9ho myelomu"@cs . . "Lenalidomid je nov\u00FD perspektivn\u00ED l\u00E9k v l\u00E9\u010Db\u011B pacient\u016F s mnoho\u010Detn\u00FDm myelomem. Tento analog thalidomidu vznikl s \u00FAmyslem zlep\u0161en\u00ED protin\u00E1dorov\u00E9ho p\u016Fsoben\u00ED, imunomodula\u010Dn\u00EDch vlastnost\u00ED, ale t\u00E9\u017E sn\u00ED\u017Een\u00ED toxicity prepar\u00E1tu. Mechanizmem protin\u00E1dorov\u00E9ho p\u016Fsoben\u00ED prepar\u00E1tu se zd\u00E1 b\u00FDt p\u016Fsoben\u00ED na bun\u011B\u010Dn\u00E9 slo\u017Eky, mikroprost\u0159ed\u00ED tumoru a zejm\u00E9na regulace produkce cytokinin\u016F. Prob\u011Bhl\u00E9 klinick\u00E9 studie f\u00E1ze I a II prok\u00E1zaly \u00FA\u010Dinnost u pacient\u016F s relabovan\u00FDm mnoho\u010Detn\u00FDm myelomem. N\u00E1sledn\u011B velk\u00E9 randomizovan\u00E9 studie prok\u00E1zaly v\u00FDhodnost terapie u relaxovan\u00FDch/ refraktern\u00EDch pacient\u016F s mnoho\u010Detn\u00FDm myelomem kombinac\u00ED lenalidomidu s dexametazonem oproti l\u00E9\u010Db\u011B dexametazonem v monoterapii. Pacienti l\u00E9\u010Den\u00ED kombinac\u00ED lenalidomidu s dexametazonem m\u011Bli v\u00FDznamn\u011B vy\u0161\u0161\u00ED l\u00E9\u010Debnou odpov\u011B\u010F i celkov\u00E9 p\u0159e\u017Eit\u00ED ne\u017E pacienti l\u00E9\u010Den\u00ED samotn\u00FDm dexametazonem. Z\u00E1sadn\u00ED toxicitou se zd\u00E1 b\u00FDt myelosupresivn\u00ED vliv lenalidomidu. Pr\u00E1ce p\u0159in\u00E1\u0161\u00ED shrnut\u00ED dostupn\u00FDch informac\u00ED o lenalidomidu v l\u00E9\u010Db\u011B mnoho\u010Detn\u00E9ho myelomu."@cs . . "CZ - \u010Cesk\u00E1 republika" . . . "The use of lenalidomide in the treatment of multiple myeloma"@en . "0862-495X" . "2"^^ . . . . "S, V" . "23" . "14110" .